GlaxoSmithKline (LON:GSK) PT Set at GBX 2,100 by Jefferies Financial Group

GlaxoSmithKline (LON:GSKGet Rating) has been given a GBX 2,100 ($26.77) price objective by investment analysts at Jefferies Financial Group in a report released on Wednesday, Borsen Zeitung reports. Jefferies Financial Group’s price objective would indicate a potential upside of 17.73% from the company’s current price.

A number of other equities research analysts have also weighed in on GSK. Berenberg Bank restated a “buy” rating and set a GBX 1,700 ($21.67) price target on shares of GlaxoSmithKline in a research note on Wednesday, March 30th. Liberum Capital upped their target price on GlaxoSmithKline from GBX 1,870 ($23.83) to GBX 1,910 ($24.34) and gave the company a “buy” rating in a research report on Tuesday, February 15th. The Goldman Sachs Group set a GBX 2,000 ($25.49) target price on GlaxoSmithKline in a research report on Friday, January 7th. Deutsche Bank Rese… set a GBX 1,600 ($20.39) target price on GlaxoSmithKline in a research report on Friday, April 22nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,500 ($19.12) target price on shares of GlaxoSmithKline in a research report on Wednesday, April 20th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, GlaxoSmithKline currently has an average rating of “Hold” and an average price target of GBX 1,697.86 ($21.64).

Shares of GlaxoSmithKline stock opened at GBX 1,783.80 ($22.74) on Wednesday. GlaxoSmithKline has a one year low of GBX 1,313.40 ($16.74) and a one year high of GBX 1,801.60 ($22.96). The company has a market capitalization of £90.69 billion and a PE ratio of 20.60. The company has a debt-to-equity ratio of 113.27, a quick ratio of 0.53 and a current ratio of 0.79. The company has a 50-day simple moving average of GBX 1,636.78 and a two-hundred day simple moving average of GBX 1,592.10.

In related news, insider Charles Bancroft purchased 2,790 shares of GlaxoSmithKline stock in a transaction dated Wednesday, March 23rd. The shares were acquired at an average price of GBX 2,114 ($26.94) per share, for a total transaction of £58,980.60 ($75,172.83). Also, insider Emma Walmsley sold 34,031 shares of GlaxoSmithKline stock in a transaction on Monday, February 14th. The stock was sold at an average price of GBX 1,610 ($20.52), for a total value of £547,899.10 ($698,316.47).

About GlaxoSmithKline (Get Rating)

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Stories

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.